Private equity firm Lyceum Capital Partners is set to acquire Synexus Clinical Research for some £18 million.

Private equity firm Lyceum Capital Partners is set to acquire Synexus Clinical Research for some £18 million.

The target company recruits patients for late-phase clinical trials, providing data for pharmaceutical and biotechnology firms.

The recommended offer is awaiting shareholder approval. CEO of Synexus, Michael Fort, said: “This deal allows Synexus to complete its international roll-out plans and provide customers with a truly competitive offering.”